Vav-2 signalling participates in the humoral immune response and B cell maturation

2001 ◽  
Vol 29 (5) ◽  
pp. A129-A129
Author(s):  
G. Doody ◽  
S. Bell ◽  
E. Vigorito ◽  
E. Clayton ◽  
S. McAdam ◽  
...  
2017 ◽  
Vol 8 ◽  
Author(s):  
Rodrigo Nunes Rodrigues-da-Silva ◽  
Isabela Ferreira Soares ◽  
Cesar Lopez-Camacho ◽  
João Hermínio Martins da Silva ◽  
Daiana de Souza Perce-da-Silva ◽  
...  

2018 ◽  
Vol 11 (1) ◽  
Author(s):  
Mario Hidalgo-Ruiz ◽  
Carlos E. Suarez ◽  
Miguel A. Mercado-Uriostegui ◽  
Ruben Hernandez-Ortiz ◽  
Juan Alberto Ramos ◽  
...  

2020 ◽  
Vol 37 ◽  
pp. 101569
Author(s):  
Sawsan Feki ◽  
Mariem Dammak ◽  
Sabrina Mejdoub ◽  
Saba Gargouri ◽  
Salma Sakka ◽  
...  

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1411-1411
Author(s):  
Ronald P. Taylor ◽  
Emily C. Whipple ◽  
Margaret A. Lindorfer ◽  
Andrew H. Ditto ◽  
Ryan S. Shanahan

Abstract Complement (C) plays a critical role in the immune response by opsonizing immune complexes (IC) and thymus-independent type 2 antigens with C3 breakdown product C3dg. We investigated the in vivo fate and handling in mice of anti-CR1/CR2 mAb 7G6. We used this rat IgG mAb as a surrogate for C3dg-opsonized IC; mAb 7G6 binds to CR1/CR2 with high affinity, blocks C3dg binding and saturates mouse B cell CR2 at inputs of only 2 ug. RIA, flow cytometry, and fluorescence immunohistochemistry were used to examine the disposition of 0.5–2 ug quantities of mAb 7G6 infused i.v. in mice. The mAb binds to circulating B cells and in the spleen binds preferentially to marginal zone (MZ) B cells. However, within 24 h MZ B cells relocate and transfer the mAb to regions rich in follicular dendritic cells (FDC). Localization of intact antigen to FDC should induce a substantial immune response, and therefore we immunized mice and monkeys i.v. with low doses (1–20 ug/kg) of prototype antigens constructed with anti-CR1/2 mAb 7G6 or anti-CR2 mAb HB135, respectively. We observed a strong immune response characterized by early development of IgG antibodies and long-lasting immunity extending out to at least one year. We applied our immunization paradigm to mouse IgG idiotypes, based on i.v. infusion of mouse IgG2a mAbs which were cross-linked with mAb 7G6. The purpose of these experiments was to determine if tolerance can be broken in order to develop a more powerful vaccine strategy to induce a cytotoxic humoral immune response to malignant B cells based on targeting the idiotype of immunoglobulin molecules expressed on their surfaces. I.V. immunization with the constructs indeed generated a mouse IgG1 immune response to two different mouse IgG2a mAbs, as demonstrated by ELISA. The immune response was idiotype specific, but some anti-isotype antibodies were also detected. Moreover, sera from immunized mice immunoprecipitated the specific radiolabeled mouse mAbs in the presence of 7.5% polyethylene glycol. This humoral immune response was also demonstrable in flow cytometry assays in which IgG1 in sera of immunized mice bound to erythrocytes opsonized with bispecific mAb constructs consisting of the IgG2a mAb crosslinked with an anti-CR1 mAb. The present approach, based on coupling the targeted immunoglobulin to an anti-CR2 mAb for delivery to FDC, may lead to a more effective immunotherapeutic vaccine compared to methods currently in clinical trials which require use of glutaraldehyde to effect crosslinking of the targeted immunoglobulin to KLH.


1993 ◽  
Vol 30 (8) ◽  
pp. 733-739 ◽  
Author(s):  
Jean-Pierre Y. Scheerlinck ◽  
Robert Deleys ◽  
Eric Saman ◽  
Lea Brys ◽  
Anja Geldhof ◽  
...  

Virology ◽  
1994 ◽  
Vol 200 (1) ◽  
pp. 98-104 ◽  
Author(s):  
Lata M. Chandrachud ◽  
Brian W. O'Neil ◽  
William F.H. Jarrett ◽  
G.Joan Grindlay ◽  
Gail M. McGarvie ◽  
...  

Author(s):  
Jakob J Malin ◽  
Veronica Di Cristanziano ◽  
Carola Horn ◽  
Elisabeth Pracht ◽  
Jorge Garcia Borrega ◽  
...  

Humoral immunodeficiency is a common finding in patients with B-cell related malignancies such as Non-Hodgkin lymphoma. Failure to induce a sufficient humoral immune response to viral pathogens such as SARS-CoV-2 can result in impaired viral clearance with prolonged viral shedding and symptomatic infections. Here we describe six COVID-19 patients with B-cell Non-Hodgkin lymphoma and impaired humoral immune response that were successfully treated with SARS-CoV-2 neutralizing monoclonal antibodies (nMABs) between June and October 2021. Patients exhibited serological vaccination failure or were unable to clear SARS-CoV-2 even after prolonged infections. Two patients presented with persistent COVID-19 for more than three months. One patient suffered from a third episode of COVID-19 despite vaccination and one patient was diagnosed by SARS-CoV-2 viremia and a positive PCR from the lower respiratory tract while subsequent nasopharyngeal swabs remained negative. In the six described cases, passive immunization with nMABs resulted in rapid and sustained clinical improvement and decrease in viral loads. SARS-CoV-2 nMABs provide a highly attractive treatment option for COVID-19 patients unable to mount a humoral immune response following vaccination or infection.


Sign in / Sign up

Export Citation Format

Share Document